

Starpharma Announces a Collaboration and License Agreement with Genentech to Develop Innovative DEP® Cancer Therapies

- Starpharma will employ its proprietary DEP® platform technology to develop dendrimer-drug conjugates that incorporate Genentech medicines for certain oncology targets.
- Starpharma will commence development activities immediately and work exclusively with Genentech in relation to those targets.
- Starpharma will receive an upfront payment of USD \$5.5 million (~AUD \$8.3 million), and is eligible for development, commercial and net sales milestones up to USD \$564 million (~AUD \$855 million), as well as tiered royalties on global net sales.

Melbourne, Australia; 22 September 2025: Starpharma (ASX: SPL, US OTC: SPHRY), an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient, today announces the signing of a collaboration and license agreement with Genentech, a member of the Roche Group, to develop potential cancer therapies that leverage Starpharma's proprietary DEP® drug delivery technology.

"We are excited to enter into this agreement, which recognises Starpharma's dendrimer technology and its potential to benefit novel drug development. It also reflects the diligent work undertaken during the past three years by Starpharma and Genentech of our previous collaborative research focused on innovating and developing cancer therapies utilising Starpharma's proprietary dendrimer technology platform, DEP®," said Cheryl Maley, CEO of Starpharma. "Genentech's world-class scientific expertise makes them an ideal collaborator, and we look forward to working together to improve patient outcomes and realise the advantages presented by Starpharma's DEP® technology platform."

Terms of the Agreement

- Starpharma will receive an upfront payment of USD \$5.5 million (~AUD \$8.3 million) and is eligible to receive up to USD \$564 million (~AUD \$855 million) in success-based development, regulatory, and commercial milestones. In addition to this amount, Starpharma is eligible for tiered royalties on global net sales of products resulting from the collaboration.
- All contracted financial terms are denominated in US dollars.
- Starpharma will employ its proprietary DEP® platform technology to generate dendrimer-drug conjugates that incorporate Genentech medicines directed to selected oncology targets.
- Starpharma will not be permitted to generate products directed to these selected oncology targets for itself or third parties.



- Starpharma has granted Genentech an exclusive worldwide license under Starpharma's IP to commercialize products resulting from the parties' collaboration.
- Genentech will be responsible for all development and commercialization of products resulting from the collaboration, which could include multiple products for each target.

"Building on three years of collaborative research, we are confident the shared commitment and strengths of both teams will enable effective execution, with the overarching goal of delivering meaningful outcomes for patients," said Cheryl Maley.

"For more than 60 years, we have been developing innovative oncology medicines, and our dedication to transforming cancer care remains unwavering," said Boris L. Zaïtra, Head of Roche Corporate Business Development. "We're committed to turning science into life-changing breakthroughs for patients."

Cheryl Maley added, "A key strategic priority for Starpharma is to build new, high-impact partnerships that unlock the full potential of our DEP® platform. By actively pursuing licensing opportunities and collaborating with leading organisations, we aim to expand market reach and enable our partners to deliver significantly improved therapies to patients worldwide."

Starpharma's DEP® platform technology offers significant benefits in drug development, including improved solubility, increased efficacy, pharmacokinetic control, and improved toxicity profiles. These advantages can be applied to a wide range of drug classes, such as small molecules, peptides, and proteins, as well as to the development of chemotherapeutics, radiotheranostics, and antibody-drug conjugates. These benefits provide companies with opportunities to enhance product attributes by differentiating their portfolios and unlocking additional treatment indications.

Visit Starpharma's new **Investor Hub** to access the latest company developments, updates, and strategic insights, and submit questions. By joining our Investor Hub, you will gain access to commentary from CEO Cheryl Maley and resources designed to help you stay connected with Starpharma's story.



Scan the QR code or visit: <https://investors.starpharma.com/link/yaGK6r>

About Starpharma

Starpharma (ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology.

Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties—including their size, structure, high degree of branching, polyvalency, and water solubility—are advantageous in medical and pharmaceutical applications.

Starpharma's portfolio of dendrimer-based products includes clinical-stage DEP® (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products.

For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on [LinkedIn](https://www.linkedin.com/company/starpharma).

WE Communications

Hannah Howlett
+61 450 648 064
WE-AUStarPharma@we-worldwide.com

Starpharma Holdings Limited

Cheryl Maley, Chief Executive Officer
Justin Cahill, Chief Financial and Operations Officer
and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067

Disclosure

This ASX Announcement was authorised for release by the Chair, Mr Rob Thomas.

Forward-Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document, nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.